Session 2: CML Management, Practicalities
Chair: Dr David Yeung

• Managing TKI toxicities
  (Dr Naranie Shanmuganathan)
• Allograft - still a role in CML?
  (Dr David Yeung)
• Molecular monitoring
  (A/Prof Susan Branford)

Managing TKI toxicities
Dr Naranie Shanmunagathan, Royal Adelaide Hospital / SA Pathology / SAHMRI

• Imatinib including bone health
• Nilotinib including; 5 year follow-up of ENESTnd, hypercholeraemia and hyperglcaemia and prolonged QTc
• Dasatinib including; 5-year follow-up of DASISION, potential strategy to reduce pleural effusions and management of DAS associated pulmonary toxicity
• Bosutinib
• Ponatinib
• Cardiovascular toxicity and TKI's
• Pancreatitis
• Managing haematological toxicity
• Summary

Allograft - still a role in CML?
Dr David Yeung - SAHMRI / Royal Adelaide Hospital

• Patient case
• Allogeneic stem cell transplantation: the most successul immunotherapy in CML
• German IIIA study
• Impact of drug development on the use of stem cell transplantation
• Strategies to reduce the risk of disease relapse in patients allografted in CML
• EBMT score for allo SCT in CML
• Graft source: BM better than PDSC in CP-CML
• Long-term follow-up after transplant for CML
• Summary
  
  

Monitoring TFR - Challenges
A/Prof. Susan Branford, SA Pathology / Universities of Adelaide and South Australia

• Gold standards of monitoring in CML
• Molecular monitoring for best patient outcomes
• Milestone molecular responses in the first 12 months
• Long-term molecular monitoring is recommended for prediction of resistance
• IM resistant BCR-ABL1 kinase domain mutations
• Long-term molecular monitoring of responsing patients is important to monitor adherence
• Regular molecular monitoring is recommended for optimal disease management
• Summary